Q-omics provides the consensus-scored TRAJ18 profile across patient tissues and cancer cell-line models. TRAJ18 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, TRAJ18 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TRAJ18 RNA expression shows 13,999 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight OV, KIRC, and LSCC as cancer lineages where TRAJ18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ18 survival associations across molecular data types. TRAJ18 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ18 RNA expression–survival associations across cancer types. High TRAJ18 expression shows unfavorable associations in GBM, LGG, DLBC and PCPG, but favorable associations in OV and HNSC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify OV as the clearest survival context for TRAJ18 RNA expression.
This table summarizes TRAJ18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ18 shows lower tumor expression in COAD, LUSC and HNSC and higher tumor expression in KIRC, BRCA and LUAD. The KIRC box plot shows higher TRAJ18 RNA expression in tumor versus normal tissue (log2 FC = +0.617, t-test p < 0.001).
This table shows molecular features associated with TRAJ18 in patient tissues and cancer cell lines. In patient samples, TRAJ18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
